Pets
“Leptospirosis, the powers that be, have now reclassified that as a core vaccine. It shouldn't be. Why? It's a highly reactive vaccine. I wouldn't give it to any dog under 10 pounds. They're going to have an anaphylactic reaction. It's not a good vaccine. It protects against four strains of lepto. There are seven that our dogs can get, so…”
Plain restatementThe canine leptospirosis vaccine has been reclassified as a core vaccine. The post asserts it should not be, on four factual grounds: (1) it causes adverse reactions at a high rate in all dogs; (2) dogs under about 10 pounds will have anaphylactic reactions; (3) it covers four leptospiral types while dogs can be infected by seven; (4) protection lasts about nine months.
General information only - not veterinary advice.
A podcast clip says the dog leptospirosis vaccine has been reclassified as a core vaccine, that it should not be, that dogs under 10 pounds will have anaphylactic reactions, that it covers four strains out of seven, and that protection lasts only about nine months. The reclassification part is correct: AAHA updated its canine vaccination guidelines in 2024 to list leptospirosis as a core vaccine for all dogs, following consensus statements from ACVIM and WSAVA, and citing rising disease prevalence. The reaction part is overstated. Published records covering more than a million vaccinated dogs show adverse events in a small fraction of dogs, with one analysis reporting 53 per 10,000 among dogs given the leptospirosis vaccine against 22.1 per 10,000 for other vaccines, and the most commonly recorded event being a nonspecific reaction rather than anaphylaxis. Smaller dogs do have higher adverse event rates than larger ones, which is a real finding, but that is not the same as every small dog reacting. The nine-month figure was not found in any source; licensing challenge studies demonstrated protection 12 months after the primary course, and up to 15 months for one component. The vaccine does cover fewer leptospiral types than exist, which is accurate as a limitation, though the specific figure of seven types could not be verified here. Whether a core recommendation for all dogs is the right call depends on local disease prevalence and is a judgement the evidence found here does not settle. General information only, not veterinary advice.
[drifted from the evidence:] Leptospirosis, the [drifted from the evidence:] powers that be, have now reclassified [drifted from the evidence:] that as a core vaccine. It [drifted from the evidence:] shouldn't be. [drifted from the evidence:] Why? It's a highly reactive vaccine. I wouldn't give it [drifted from the evidence:] to any dog under 10 pounds. [drifted from the evidence:] They're going to have [drifted from the evidence:] an anaphylactic [drifted from the evidence:] reaction. It's not a good vaccine. It [drifted from the evidence:] protects against four [drifted from the evidence:] strains of lepto. There are seven that our dogs can [drifted from the evidence:] get, so we're not even giving them full protection. It can be [drifted from the evidence:] very reactive in all dogs, and it actually only lasts [drifted from the evidence:] probably nine months. [drifted from the evidence:] It's just not a great vaccine." (Instagram post headline: "The leptospirosis vaccine for dogs should not be classified as a core vaccine despite having been reclassified as one.")
The [added by the neutral restatement:] canine leptospirosis vaccine has been reclassified as a core vaccine. [added by the neutral restatement:] The post asserts it [added by the neutral restatement:] should not be, [added by the neutral restatement:] on four factual grounds: (1) it [added by the neutral restatement:] causes adverse reactions at a high rate in all dogs; (2) dogs under [added by the neutral restatement:] about 10 pounds [added by the neutral restatement:] will have anaphylactic [added by the neutral restatement:] reactions; (3) it [added by the neutral restatement:] covers four [added by the neutral restatement:] leptospiral types while dogs can be [added by the neutral restatement:] infected by seven; (4) protection lasts [added by the neutral restatement:] about nine months.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- The reclassification happened. AAHA updated its 2022 canine vaccination guidelines in 2024 to list leptospirosis as a recommended core vaccine for all dogs, after ACVIM and WSAVA consensus statements and its own task force recommendation.
- The vaccine's coverage is narrower than the organism's diversity. Commonly used multivalent canine products cover four serogroups, and the European tetravalent study covers Canicola, Icterohaemorrhagiae, Grippotyphosa and Australis. Dogs can be infected by leptospires outside the serogroups in a given product.
- Protection is not absolute. A systematic review notes leptospires have been isolated from vaccinated dogs.
- Small dogs do show higher adverse event rates after vaccination in general. The published analyses report rates inversely related to body weight, with the highest rates in dogs of 5 kg or less, which is close to the 10 pound threshold the post uses.
- The leptospirosis component is associated with a measurably higher adverse event rate than other canine vaccines. One analysis reported 53 per 10,000 in lepto-vaccinated dogs against 22.1 per 10,000 in others, and the 2023 adjusted odds ratio was 1.49.
- "They're going to have an anaphylactic reaction" states a near-certainty where the data show a small minority. At 53 adverse events per 10,000 lepto-vaccinated dogs, about 99.5 percent of dogs in that dataset had no recorded event of any kind within the observation window, and the most common recorded event was a nonspecific vaccine reaction rather than anaphylaxis. Anaphylaxis is a subset of an already small number.
- "Highly reactive" and "very reactive in all dogs" overstate an effect the sources size as modest. An adjusted odds ratio of 1.49 means roughly a one-and-a-half-fold relative increase on a low baseline, not a high absolute risk, and the same analyses attribute increased risk to small body weight, young age, breed and the number of injections given at one visit, not to the leptospirosis component alone.
- "It only lasts probably nine months" runs against the published challenge data. Licensing studies demonstrated protection at 12 months after the primary two-dose course, with 15 months reported for the Grippotyphosa fraction of one product. No source was found supporting a nine-month figure.
- "The powers that be have reclassified it" leaves out who and what kind of decision this is. The change was made by veterinary professional bodies issuing guidelines, following consensus statements, and the stated reason was rising disease prevalence. A core designation in a guideline is a recommendation to veterinarians, not a regulation or a legal requirement, and WSAVA's global framing differs from AAHA's US one.
- The four-versus-seven framing is presented as showing the vaccine fails. Partial coverage is real, but the sources do not treat coverage of fewer than all serogroups as evidence that a vaccine does not work; the challenge studies measure protection against the serogroups included, including prevention of renal carriage and urinary shedding, which also bears on human exposure since the organism is zoonotic.
- A practitioner's clinical view is the origin of these figures, not their evidence. The post's numbers are asserted in a podcast clip without citation; this check graded the published evidence behind each one, which is where the gaps appear.
- The "seven serovars dogs can get" figure could not be matched to any retrieved source. Many pathogenic Leptospira serovars are described, and which ones infect dogs varies by region and over time, so neither the number seven nor a competing number was verified here.
- No source was retrieved giving an anaphylaxis-specific rate, as distinct from all adverse events, for dogs under about 4.5 kg receiving leptospirosis vaccine. The body-weight gradient is documented; the specific severe-reaction rate in that weight band is not established by what was found.
- Whether a core recommendation for all dogs is the right policy is a judgement about benefit and risk across a population, and it depends on local disease prevalence, which the AAHA announcement cites as the driver and which differs by region. The evidence retrieved does not settle that judgement either way.
- Duration of immunity beyond 12 to 15 months, and how experimental challenge protection translates to field protection, were not established by the sources found.
- Funding statements for the individual duration-of-immunity and adverse-event studies were not retrieved, and manufacturer involvement in licensing challenge studies is the norm in this field.
On the reclassification: AAHA's 2022 Canine Vaccination Guidelines were updated in 2024 to include leptospirosis as a recommended core vaccine for all dogs. AAHA states the change in status from non-core to core followed consensus statements from the American College of Veterinary Internal Medicine and the World Small Animal Veterinary Association, and the recommendation of AAHA's vaccine guidelines task force, with the stated reason being a substantial increase in the prevalence of the disease over the years AAHA has published guidelines. The original 2022 text had listed it as noncore while noting disagreement: core examples were canine distemper virus, canine adenovirus type 2, canine parvovirus type 2 and rabies, with leptospirosis, Bordetella, Lyme, influenza and rattlesnake toxoid considered noncore, although some Task Force members asserted leptospirosis should be core based on increasing geographical prevalence. Trade reporting on the 2023 ACVIM consensus statement describes the recommendation that every dog should receive a leptospirosis vaccine every year. On reactivity: the large US electronic-record work found a vaccine-associated adverse event rate of 38.2 per 10,000 dogs across records for 1,226,159 dogs, and the adverse event rate was generally inversely related to body weight, with the largest rates in dogs of 5 kg or less, and also associated with increasing number of vaccines administered, sex and neuter status, and younger age. The 2023 five-year JAVMA analysis reports risk of adverse events increasing with decreasing body weight, breed and multiple injections also associated with increased adverse event reports within three days of vaccination, and a multivariable adjusted odds ratio for the leptospirosis vaccine of 1.49 (95% CI, 1.44 to 1.54). A veterinary academic blog summarising a lepto-specific analysis reports an overall adverse event rate of 26.3 per 10,000 dogs, 53 per 10,000 in dogs vaccinated against leptospirosis and 22.1 per 10,000 in dogs vaccinated against anything else, with "nonspecific vaccine reaction" the most common event recorded in both groups. On duration of protection: a European tetravalent vaccine achieved significant protective immunity in dogs 12 months after a two-dose primary schedule against strains of serogroups Canicola, Icterohaemorrhagiae, Grippotyphosa and Australis; a licensed quadrivalent vaccine was assessed for clinical signs, leptospiremia, leptospiruria, renal carriage and renal lesions after Leptospira Australis challenge performed 2 weeks and 12 months after primary vaccination; and a systematic review records that immunity reportedly lasts 12 months in experimental studies, with serovar-specific immunity found to last up to fifteen months for serovar Grippotyphosa, while noting this protection is not absolute as leptospires have been isolated from vaccinated dogs.
Complete reasoning
The reply is formatted for pasting into the thread where the claim is circulating.
Ask this case
Answers come only from the case file above; nothing is added.
Was the leptospirosis vaccine really reclassified as core?
Yes. AAHA updated its canine vaccination guidelines in 2024 to list leptospirosis as a recommended core vaccine for all dogs, following consensus statements from ACVIM and WSAVA and its own task force recommendation.
Will small dogs really have an anaphylactic reaction to this vaccine?
No, that claim overstates the risk. One analysis found 53 adverse events per 10,000 lepto-vaccinated dogs, meaning about 99.5 percent had no recorded event, and the most common event reported was a nonspecific reaction rather than anaphylaxis. Small dogs do show higher adverse event rates than larger dogs, but that is not the same as every small dog having a severe reaction.
Does the vaccine only protect against four of seven leptospira strains?
The vaccine covering fewer types than exist is accurate as a general limitation, and commonly used products cover four serogroups. However, the specific claim that there are exactly seven strains dogs can get could not be verified in the case file.
Does protection from the vaccine really wear off after nine months?
No, the evidence found does not support that figure. Licensing challenge studies showed protection lasting 12 months after the primary two-dose course, with one component showing protection up to 15 months, and no source supported a nine-month duration.
Is it fair to call the vaccine 'highly reactive' or 'very reactive in all dogs'?
This overstates what the data show. The leptospirosis vaccine does have a measurably higher adverse event rate than other canine vaccines, with an adjusted odds ratio of about 1.49, but this reflects a modest relative increase on a low baseline rate, not a high absolute risk affecting all dogs.